Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucagon-like peptide-1 mimetics, optimal for Asian type 2 diabetes patients with and without overweight/obesity: meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-11-16
DOI
10.1038/s41598-017-16018-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
- (2017) Kun-Ho Yoon et al. Diabetes & Metabolism Journal
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes:post hocanalysis of data from four phase III trials
- (2016) J. A. Davidson et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial
- (2016) L. Zang et al. DIABETES OBESITY & METABOLISM
- Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial
- (2016) Yutaka Seino et al. Journal of Diabetes Investigation
- Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients
- (2016) Xiaoping Chen et al. Journal of Diabetes
- Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients
- (2015) Ping Feng et al. ACTA PHARMACOLOGICA SINICA
- Impact of classical risk factors of type 2 diabetes among Asian Indian, Chinese and Japanese populations
- (2015) L. He et al. DIABETES & METABOLISM
- Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study
- (2015) J. Miyagawa et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study
- (2015) E. Araki et al. DIABETES OBESITY & METABOLISM
- Type 2 diabetes mellitus incidence in Chinese: Contributions of overweight and obesity
- (2015) Chao Wang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes
- (2015) Kumiko Tanaka et al. ENDOCRINE JOURNAL
- A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes
- (2015) Yuichiro Inoue et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
- (2014) Y. G. Kim et al. DIABETES OBESITY & METABOLISM
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
- (2014) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
- (2014) Yasuo Terauchi et al. ENDOCRINE JOURNAL
- Efficacy and Safety Comparison of Add-on Therapy with Liraglutide, Saxagliptin and Vildagliptin, All in Combination with Current Conventional Oral Hypoglycemic Agents Therapy in Poorly Controlled Chinese Type 2 Diabetes
- (2014) C.-J. Li et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)
- (2014) W. Xu et al. JOURNAL OF INTERNAL MEDICINE
- Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S
- (2014) Yukiko Onishi et al. Journal of Diabetes Investigation
- Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study
- (2014) Yumie Takeshita et al. Journal of Diabetes Investigation
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
- (2012) Chun-jun Li et al. Cardiovascular Diabetology
- Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study
- (2012) Nobuya Inagaki et al. CLINICAL THERAPEUTICS
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus
- (2012) Linong Ji et al. Journal of Diabetes Investigation
- Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
- (2010) Y. Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
- (2010) W. Yang et al. DIABETES OBESITY & METABOLISM
- Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
- (2010) Takashi Kadowaki et al. Journal of Diabetes Investigation
- Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
- (2009) K. Kaku et al. DIABETES OBESITY & METABOLISM
- Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
- (2009) Takashi KADOWAKI et al. ENDOCRINE JOURNAL
- Diabetes in Asia
- (2009) Juliana C. N. Chan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Diabetes in Asia
- (2009) Ambady Ramachandran et al. LANCET
- Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes
- (2008) Y. Seino et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
- (2008) Yan Gao et al. DIABETES RESEARCH AND CLINICAL PRACTICE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started